

Study	Indication	Line	Status	Contact person	Details
Lung Cancer					
PEARLS	NSCLC, Stage II-III	adjuvant	open	OA Dr. Overbeck F-OA Dr. Kaiser SN Frau Tomala SV Frau Wolff-Menzler	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy
STARTRK-2	Advanced stage NSCLC, NTRK1/2/3	≥ 1 st line	open	OA Dr. Overbeck OÄ PD Dr. Schanz SN Frau Tomala SV Frau Goldmann	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, (...) Gene Rearrangements
GEOMETRY-1 =CINC280A2201	Advanced stage NSCLC, MET Exon 14skip. Mut.	1 st line	open	OA Dr. Overbeck F-OA Dr. Kaiser SN Frau Tomala SV Frau Wolff-Menzler	A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) for advanced/metastatic disease
ELEVATION-101 group E	met. NSCLC, non-squamous cell carcinoma only	1 st line	closed	OA Dr. Overbeck (= LKP) OA Dr. Brökers SN Frau Klepl SN Frau Tomala	Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients Amendment group E: + Canakinumab
VISION	Advanced stage NSCLC, METexon14mut (tissue+/-LBx) or MET ampl (LBx)	1 st -3 rd line	open	OA Dr. Overbeck OÄ PD Dr. Schanz SN Frau Tomala SV Frau Klepl	A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification
CRISP Registry	NSCLC, stage II-IV	any	open	OA Dr. Overbeck SN Frau Wolff-Menzler SN Frau Tomala	Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients
CANOPY-1	Advanced stage NSCLC	1 st line	open	OA Dr. Overbeck OÄ PD Dr. Schanz SN Frau Tomala SV Frau Wolff-Menzler	A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous NSCLC subjects
MK-7339-006	met. non-squamous NSCLC stage IV	1 st line	coming soon	OA Dr. Overbeck OA Dr. Brökers SN Frau Tomala SV Frau Wolff-Menzler	Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer
MK-7339-008	met. squamous NSCLC stage IV	1 st line	coming soon	OA Dr. Overbeck OA Dr. Brökers SN Frau Tomala SV Frau Wolff-Menzler	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
LIBRETTO-431	Advanced or metastatic RET act. Solid tumors incl. NSCLC	1st line	coming soon	OA Dr. Overbeck OA Dr. Brökers SN Frau Tomala SV Frau Wolff-Menzler	Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Contact:

sarah.torke@med.uni-goettingen.de

friederike.braulke@med.uni-goettingen.de

Lung cancer studies:

tobias.overbeck@med.uni-goettingen.de

Lungenfachklinik Immenhausen (LKI)

Studiename	Studienkurzbeschreibung	Legende
GO29527 / Sponsor: F. Hoffmann-La Roche Ltd	A Phase III, Open label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PDL1 Antibody) Compared With Standard of Care Following Adjuvant Cisplatin-based Chemotherapy in PDL-1 Selected Patients with Completely Resected Stage IB-IIIa Non-Small Cell Lung Cancer	Rekrutierung beendet
GO29437 / Sponsor: F. Hoffmann-La Roche Ltd	A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY-NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER	

<p>GO29537 / Sponsor: F. Hoffmann-La Roche Ltd</p>	<p>A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL FOR CHEMOTHERAPY-NAÏVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER</p>
<p>ADAURA D5164C00001 / Sponsor: Fa. AstraZeneca</p>	<p>A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)</p>
<p>CA209-451 Study / Sponsor: Bristol-Myers Squibb</p>	<p>A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy</p>
<p>CA209-743 / Sponsor: Bristol-Myers Squibb (BMS)</p>	<p>A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma / Titel des Prüfplans: Eine randomisierte, offene Phase-III-Studie zu Nivolumab in Kombination mit Ipilimumab gegenüber Pemetrexed mit Cisplatin oder Carboplatin als Erstlinientherapie bei inoperablem Pleuramesotheliom</p>

<p>(D419MC00004) POSEIDON Studie / Sponsor: AstraZeneca</p>	<p>A Phase II, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for 1st-Line Treatment in Patients with Metastatic Non-Small-Cell-Lung-Cancer (NSCLC) (POSEIDON)</p>
<p>CA209-9LA / Sponsor: Bristol Myers Squibb (BMS)</p>	<p>A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)</p>
<p>CA209-9LA / Sponsor: Bristol Myers Squibb (BMS)</p>	<p>A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAGE IIIB NOT AMENABLE FOR MULTIMODALITY TREATMENT) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER WHO ARE DEEMED UNSUITABLE FOR PLATINUM-CONTAINING THERAPY</p>
<p>AIO-TRK-0117 NintNivo - Sponsor: AIO-Studien-gGmbH</p>	<p>Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology – An AIO phase Ib trial.</p>
<p>MK-3475-671 / MSD SHARP & DOHME GMBH</p>	<p>Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB(N1) or IIIA Non-Small Cell Lung Cancer</p>

<p>GO39733 / Fa. Roche</p>	<p>A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS</p>
<p>BO40336 ALINA / Fa. Roche</p>	<p>A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS > 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER</p>
<p>205801 ENTRÉE / Fa. GSK</p>	<p>A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants</p>
<p>CA209-73L / Fa. Bristol-Myers Squibb Research and Development (BMS)</p>	<p>A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)</p>

MK7339-006 / Fa. Merck Sharp & Dohme Corp. (MSD)	A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
MK7339-008 / Fa. Merck Sharp & Dohme Corp. (MSD)	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Kontakt: SN Frau Vorreiter nvorreiter@lungenfachklinik-immenhausen.de

PD Dr. A. Rittmeyer

Prof. Dr. S. Andreas